# Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

> **NCT05755854** · PHASE1 · UNKNOWN · sponsor: **Anhui Provincial Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Hematologic Diseases

## Interventions

- **BIOLOGICAL:** allogeneic γ9δ2 T Cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Zoredronic acid

## Key facts

- **NCT ID:** NCT05755854
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-03
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05755854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05755854, "Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05755854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*